Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KamadaKMDA -0.73%86 Return-on-Tangible-Equity is 26.59% as of Jun. 2026, which is 127% above its 10-year median of 11.72. GuruFocus rates KMDA with a GF Score™ of 86/100 and a GF Value™ of $8.60 (Fairly Valued). The stock has 1 warning sign investors should review. Among 896 Drug Manufacturers companies, Kamada ranks better than 72.1% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Kamada's annualized net income for the quarter that ended in Jun. 2026 was $37.0 Mil. Kamada's average shareholder tangible equity for the quarter that ended in Jun. 2026 was $139.3 Mil. Therefore, Kamada's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 26.59%.
The historical rank and industry rank for Kamada's Return-on-Tangible-Equity or its related term are showing as below:
KMDA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -9.67 Med: 11.72 Max: 22.1
Current: 16.19
During the past 13 years, Kamada's highest Return-on-Tangible-Equity was 22.10%. The lowest was -9.67%. And the median was 11.72%.
KMDA's Return-on-Tangible-Equity is ranked better than 72.1% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.515
vs KMDA: 16.19
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Kamada Return-on-Tangible-Equity Related Terms
Kamada Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Kamada's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KMDA vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kamada Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kamada's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Kamada's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 26.59% mean?
Kamada (KMDA) has a Return-on-Tangible-Equity of 26.59% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Kamada and its competitors. This is 127% above median its historical median of 11.72. According to the industry distribution chart, Kamada ranks #250 out of 896 companies in the Drug Manufacturers industry, placing it in the top 27.9%.
Is Kamada's Return-on-Tangible-Equity too high?
Kamada's current Return-on-Tangible-Equity of 26.59% is 127% above median its 10-year median of 11.72. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.52. Kamada's value of 26.59% is 253.8% above this industry median. Based on the distribution chart, Kamada ranks #250 out of 896 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kamada has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kamada's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kamada ranks #250 out of 896 companies for Return-on-Tangible-Equity. This puts Kamada in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.52. Kamada's value of 26.59% is 253.8% above this benchmark. While the company's 10-year median is 11.72 vs. the industry median of 7.52, Kamada has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.52, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kamada's current Return-on-Tangible-Equity of 26.59% is 253.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Kamada and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kamada's current Return-on-Tangible-Equity is 26.59%, which is 127% above median its own 10-year median of 11.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kamada stock overvalued right now?
Based on GuruFocus' analysis, Kamada (KMDA) is currently considered Fairly Valued. The stock's GF Value™ is $8.60, compared to a current price of $8.21 — trading 4.5% below its estimated fair value. The current Return-on-Tangible-Equity is 26.59%, which is 127% above median its 10-year median of 11.72 and 253.8% above the Drug Manufacturers industry median of 7.52. Kamada's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Kamada (KMDA), the current Return-on-Tangible-Equity is 26.59% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kamada (KMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Kamada stock appears to be undervalued.
The current stock price of $8.21 is trading 4.5% below its estimated GF Value™ of $8.60.
GuruFocus considers Kamada to be Fairly Valued.
Key valuation signals for KMDA:
Return-on-Tangible-Equity: 26.59% (127% above median its 10-year median of 11.72)
GF Value™: $8.60 vs. price of $8.21 (4.5% below fair value)
Industry Position: 253.8% above the Drug Manufacturers median (#250 of 896)
No single metric tells the full story. See the KMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
86GF Score
Get the complete analysis for KMDA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMDA has been successfully added to your 
